To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of ...

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.

We're very fortunate where I work in Philadelphia to have a robust pediatric team and also a robust adult-focused care team for muscular dystrophy. And so our ability to have this transition ...

Practical pain relief strategies for people with DMD and their caregivers, covering daily care, medications, and emotional support.

The purpose of this report is to re-evaluate such a therapeutic program in muscular dystrophy when the drugs ... Two children and 1 adult with neurogenic weakness were also evaluated.

Two forms of treatment that are very helpful for hypotonia are physical therapy and occupational therapy ... Possible causes include Down syndrome, muscular dystrophy, cerebral palsy, and Prader-Willi ...

MONDAY, April 28, 2025 (HealthDay News) -- Adults with peanut allergies can be safely treated using exposure therapy to increase their resistance, new clinical trial results show. More than two ...

This was the first trial to test exposure therapy in adults Originally published on healthday.com, part of the BLOX Digital Content Exchange.

provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular dystrophy (DMD) If approved by the European Commission, Duvyzat will be available for ...

How Much Does an Occupational Therapy Assistant Make? Occupational Therapy Assistants made a median salary of $67,010 in 2023. The best-paid 25% made $77,290 that year, while the lowest-paid 25% ...

It’s been nearly two years since Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for Duchenne muscular dystrophy (DMD) developed by Sarepta Therapeutics, was approved by the U.S. Food and ...